David Peng

David Peng is a professional with a strong educational background and diverse experience in the fields of chemical engineering, biology, business development, investment banking, and biotechnology.

He received his B.S. and B.A. degrees in Chemical Engineering and Biology from The Johns Hopkins University and furthered his education by obtaining a Ph.D. and M.S.E. in Chemical Engineering from the University of Michigan.

David has held various key positions in notable organizations. Currently, he serves as the Principal of Science & Technology at Alexandria Venture Investments within Alexandria Real Estate Equities, Inc.

Prior to his role at Alexandria, David Peng served as the Director of Business Development at Sangamo Therapeutics, Inc., showcasing his expertise in fostering strategic partnerships and collaborations within the biotechnology industry.

His experience also extends to the financial sector where he held positions at Bank of America Merrill Lynch and Guggenheim Partners as Vice President and Associate in Healthcare Investment Banking respectively.

With a solid background in equity research, David Peng worked at Stifel Financial Corp. and Canaccord Genuity Inc. as an Associate in Biotechnology Equity Research, honing his analytical skills and market insights.

Before delving into the realms of finance and business, David kickstarted his career in the scientific domain with roles such as Senior Applications Specialist at Life Technologies, Research Associate at Genentech, Inc., and Research Intern at Johnson & Johnson, Inc.

Throughout his career journey, David Peng's passion for innovation, business development, and scientific advancements has been evident, making him a well-rounded professional in the intersection of science, technology, and investment.